B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co
$ 16.99 · 4.7 (233) · In stock
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]
Where do lawsuits against B. Braun over cancer-causing chemical stand?
Global Oncology
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® - Cytosorbents
B. Braun Group on LinkedIn: #era #hemodialysisconcentrate #renalcare #dialysis…
Continuous Renal Replacement Therapy (CRRT) Market Drivers & Opportunities
Digital Diabetes Management Market Size, Trends & Forecast
B. Braun Appoints James Allen as New Chief Financial Officer
Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk
B. Braun and CytoSorbents Announce Global Co-Marketing Agreement
Continuous Renal Replacement Therapy (CRRT) Market Drivers & Opportunities
Organization, Facts & Figures
In this image released on Tuesday, March 2, 2021, the OMNI
Newsroom